Ionis Slashes Key Drug Revenue Outlook by 50%, Overshadowing Otherwise Solid Earnings来源:Barrons发布于 2026-11-09Shares of Ionis Pharmaceuticals sink after it slashes full-year revenue guidance for one of its flagship drugs.相关标的:IONS继续访问返回新闻本文内容来自外部来源,点击「继续访问」将跳转到原始发布站点。